Geron Corporation (GERN) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Geron Corporation.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.000 -- 00:00:05.020 After the speaker's remarks, there will be a question and answer session. 00:00:05.020 -- 00:00:10.120 If you would like to ask a question during that time, simply press star, then the 00:00:10.120 -- 00:00:15.160 number one on your telephone keypad. I would now like to turn the call over to 00:00:15.160 -- 00:00:21.700 David Borah, Head of Investor Relations. David, please go ahead. 00:00:21.940 -- 00:00:26.940 Good morning, everyone. Welcome to Geron Corporation's second quarter 2025 earnings 00:00:26.940 -- 00:00:31.820 conference call. Before we begin, please note that during the course of this presentation 00:00:31.820 -- 00:00:35.720 and question and answer session, we will be making forward-looking statements regarding 00:00:35.720 -- 00:00:41.020 future events, performance, plans, expectations, and other projections, 00:00:41.020 -- 00:00:45.620 including those relating to the launch, commercial opportunity, therapeutic potential 00:00:45.620 -- 00:00:50.760 of Ritello, anticipated clinical and commercial events and related timelines, 00:00:50.760 -- 00:00:55.440 the sufficiency of Geron's financial resources, and other statements that are not historical 00:00:55.440 -- 00:01:00.680 facts. Actual events or results could differ materially. 00:01:00.680 -- 00:01:04.980 Therefore, I refer you to the discussion under the heading risk factors in Geron's most 00:01:04.980 -- 00:01:09.960 recent periodic report filed with the SEC, which identifies important factors that could 00:01:09.960 -- 00:01:14.340 cause actual results to differ materially from those contained in the forward-looking 00:01:14.340 -- 00:01:18.640 statements and our future updates to those risk factors. 00:01:18.640 -- 00:01:23.360 Geron undertakes no duty or o...